Steigerwald Gordon & Koch Inc. Boosts Stock Holdings in Abbott Laboratories (NYSE:ABT)

Steigerwald Gordon & Koch Inc. boosted its holdings in Abbott Laboratories (NYSE:ABT) by 3.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,247 shares of the healthcare product maker’s stock after acquiring an additional 150 shares during the quarter. Steigerwald Gordon & Koch Inc.’s holdings in Abbott Laboratories were worth $484,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Nomura Holdings Inc. lifted its holdings in shares of Abbott Laboratories by 1,566.0% during the 4th quarter. Nomura Holdings Inc. now owns 34,986 shares of the healthcare product maker’s stock valued at $3,851,000 after buying an additional 32,886 shares during the period. Hancock Whitney Corp increased its position in shares of Abbott Laboratories by 5.2% during the 4th quarter. Hancock Whitney Corp now owns 25,353 shares of the healthcare product maker’s stock valued at $2,791,000 after purchasing an additional 1,249 shares during the last quarter. True Wealth Design LLC lifted its stake in shares of Abbott Laboratories by 1,677.8% in the 4th quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock worth $35,000 after purchasing an additional 302 shares during the period. Power Corp of Canada bought a new stake in Abbott Laboratories during the fourth quarter valued at approximately $372,000. Finally, First Long Island Investors LLC raised its position in Abbott Laboratories by 8.5% in the fourth quarter. First Long Island Investors LLC now owns 344,843 shares of the healthcare product maker’s stock worth $37,957,000 after acquiring an additional 27,150 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.0 %

ABT stock traded up $0.02 during mid-day trading on Thursday, reaching $115.97. 1,127,437 shares of the stock traded hands, compared to its average volume of 5,725,030. The business has a 50-day moving average price of $112.93 and a two-hundred day moving average price of $108.26. The stock has a market capitalization of $201.75 billion, a PE ratio of 36.12, a PEG ratio of 2.86 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.68. Abbott Laboratories has a one year low of $89.67 and a one year high of $121.64.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The firm had revenue of $10.38 billion for the quarter, compared to analysts’ expectations of $10.37 billion. During the same quarter in the prior year, the firm posted $1.08 earnings per share. The company’s quarterly revenue was up 4.0% on a year-over-year basis. Equities research analysts expect that Abbott Laboratories will post 4.66 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $2.20 annualized dividend and a dividend yield of 1.90%. Abbott Laboratories’s dividend payout ratio is currently 68.54%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ABT. Citigroup boosted their price objective on shares of Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Piper Sandler Companies started coverage on Abbott Laboratories in a research note on Thursday, September 19th. They set an “overweight” rating and a $131.00 price objective for the company. Edward Jones lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Evercore ISI raised their price objective on shares of Abbott Laboratories from $120.00 to $124.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Barclays increased their price target on Abbott Laboratories from $140.00 to $143.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $125.15.

Insider Buying and Selling

In other news, CEO Robert B. Ford sold 141,679 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the sale, the chief executive officer now owns 220,059 shares of the company’s stock, valued at approximately $25,617,068.19. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.10% of the stock is owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.